Ketamine for depression: all studies (page 27)

Kappa-Opioid Receptor Antagonism Prolongs the Antidepressant Effects of Ketamine in Adult Mice with Depression-like Behavior Induced by Adolescent Chronic Unpredictable Stress

International Journal of Molecular Sciences March 20, 2026 Ana Zivanovic, Milos Mitic, Iva Lukic et al.

Major depressive disorder (MDD) is a highly prevalent psychiatric illness for which rapid-acting antidepressants such as ketamine provide only transient benefit. Because κ-opioid receptor (KOR) signaling contributes to stress-related dysphoria and impaired neuroplasticity, we examined whether KOR antagonism could prolong ketamine’s antidepressant-like effects in a mouse model of adolescent...

DOI: 10.3390/ijms27062815

[Esketamine alleviates depression-like behaviors in mice with chronic restraint stress by activating glutamatergic neurons in the medial prefrontal cortex].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University March 20, 2026 Zhuoning Zhang, Xinyu Hao, Fuyang Cao et al.

To investigate the regulatory role of glutamatergic neurons in the medial prefrontal cortex (mPFC) in the antidepressant effects of esketamine. A total of 150 male C57BL/6J mice were randomly divided into 15 groups (n=10). The mice subjected to the chronic restraint stress (CRS), and those exhibiting depressive-like behaviors following CRS received either esketamine or saline treatment, and...

DOI: 10.12122/j.issn.1673-4254.2026.03.02 Full text Depression Esketamine Glutamatergic neurons Medial prefrontal cortex

Integrated network pharmacology and comprehensive bioinformatics analysis to identify the mechanisms and molecular targets of ketamine in ischemic stroke-depression comorbidity.

PLoS One March 18, 2026 Yunfei Shu, Yinhao Guo, Suihan Xu et al.

Comorbid depression following ischemic stroke is a debilitating condition with complex pathophysiology. Although ketamine demonstrates rapid antidepressant effects, its molecular mechanisms in the context of this comorbidity are poorly understood. We employed a network pharmacology approach to hypothesize potential molecular targets and pathways of ketamine relevant to both ischemic stroke and...

DOI: 10.1371/journal.pone.0343918 Full text Ketamine Depression Humans Computational biology +7

Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.

BMC Psychiatry March 17, 2026 Bernhard T Baune, Kevin Rosemann, Dimitri Hefter et al. 2 citations

BACKGROUND: Intranasal esketamine has recently emerged as an innovative treatment option for treatment-resistant depression (TRD). This retrospective, uncontrolled study aimed to evaluate the real-world effectiveness of esketamine in an naturalistic inpatient setting and explore demographic and clinical factors associated with treatment response. METHODS: We conducted a chart review of 101...

DOI: 10.1186/s12888-026-07980-8 Full text Mdd Humans Antidepressive agents Treatment outcome +10

Decoding the molecular network communication mechanism of ketamine's antidepressant effects.

Psychopharmacology March 16, 2026 Ye Li, Qilong Cheng, Guoxin Lin et al.

RATIONALE: Major Depressive Disorder (MDD) is a global public health burden, with traditional monoaminergic antidepressants facing critical limitations including slow onset, adverse side effects, and high rates of treatment resistance (TRD). Ketamine, a rapid-acting agent with sustained antidepressant effects, has revolutionized depression treatment paradigms but challenges conventional...

DOI: 10.1007/s00213-026-07028-5 Full text Depression Ketamine Mechanism of action Molecular network regulation +1

Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein.

Journal of Affective Disorders March 15, 2026 Patrícia Cavalcanti-Ribeiro, Lara Carvalho Araújo Melo De Souza, Vagner Deuel O de Tavares et al.

Treatment-resistant depression (TRD) remains a major clinical challenge, with inflammation increasingly implicated in its pathophysiology. C-reactive protein (CRP), an accessible biomarker, has emerged as a potential predictor of antidepressant response. While intravenous and intranasal ketamine have shown anti-inflammatory effects, evidence linking inflammation and clinical outcomes remains...

DOI: 10.1016/j.jad.2025.120877 Full text Esketamine Treatment-resistant depression Antidepressant response C-reactive protein +2

Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review

Cureus March 14, 2026 Suneha Shelke, Rusheeth Thummalapally

Treatment-resistant depression (TRD) presents a complex clinical challenge, particularly when comorbid with substance use disorders (SUDs) or other compulsive behaviors. With up to a third of major depressive disorder (MDD) patients failing to respond to standard antidepressant therapies, there is growing interest in interventions such as esketamine, a glutamatergic N-methyl-D-aspartate (NMDA)...

DOI: 10.7759/cureus.105219 Full text Major depressive disorder Narrative review Depression economics Current fluid +2

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports.

Clinics and practice March 13, 2026 Alessandro Guffanti, Matteo Leonardi, Natascia Brondino et al.

Major depressive disorder (MDD) is a leading cause of disability worldwide and contributes significantly to the global burden of disease. Recent data show an increasing prevalence of treatment-resistant depression (TRD). Patients with autism spectrum disorder (ASD) often exhibit MDD as a comorbidity and it is often resistant to conventional treatments. ASD determines emotional dysregulation and...

DOI: 10.3390/clinpract16030061 Full text Esketamine Major depressive disorder Treatment-resistant depression Autism spectrum disorder +4

Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS.

International Journal of Psychiatry in Clinical Practice March 11, 2026 Michele Prato, Matteo Carminati, Filippo Frizzi et al. 1 citation

Background: Treatment-Resistant Depression (TRD) often persists despite adequate pharmacotherapy. Intranasal Esketamine and accelerated repetitive Transcranial Magnetic Stimulation (aTMS) are rapid-acting options, but head-to-head comparisons remain limited. Methods: We conducted a retrospective study on TRD patients receiving either aTMS (n = 18) or Intranasal Esketamine (n = 22). Depression...

DOI: 10.1080/13651501.2026.2642680

Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities

Pharmacological Reports March 11, 2026 Benjamin D. Brody, Dora Kanellopoulos 1 citation

Recent retrospective analyses have shown that individuals with comorbid Substance Use Disorders (SUDs) are overrepresented among responders to ketamine for Treatment Resistant Depression (TRD). Ketamine is an effective treatment for depression and also a potential substance of misuse. The authors contrast a mechanistic pathway with a possible expectancy effect to account for these findings, and...

DOI: 10.1007/s43440-026-00843-9 Full text

Research